

John B A G Haanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/423437/publications.pdf>

Version: 2024-02-01

389
papers

69,011
citations

4388

86
h-index

718

252
g-index

408
all docs

408
docs citations

408
times ranked

56216
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723. | 27.0 | 13,065 |
| 2 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516. | 27.0 | 6,976 |
| 3 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34. | 27.0 | 6,773 |
| 4 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356. | 27.0 | 3,589 |
| 5 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546. | 27.0 | 2,484 |
| 6 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115. | 27.0 | 1,824 |
| 7 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142. | 1.2 | 1,744 |
| 8 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888. | 27.0 | 1,572 |
| 9 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451. | 13.7 | 1,175 |
| 10 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636. | 27.0 | 909 |
| 11 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , 2014, 15, 323-332. | 10.7 | 890 |
| 12 | Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. <i>Cell</i> , 2019, 176, 775-789.e18. | 28.9 | 760 |
| 13 | Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e439-e442. | 1.6 | 746 |
| 14 | Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020, 26, 566-576. | 30.7 | 736 |
| 15 | Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622. | 1.6 | 720 |
| 16 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014, 508, 118-122. | 27.8 | 702 |
| 17 | The "cancer immunogram". <i>Science</i> , 2016, 352, 658-660. | 12.6 | 655 |
| 18 | Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. <i>Cell</i> , 2018, 174, 1586-1598.e12. | 28.9 | 644 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nature Medicine</i> , 2018, 24, 1655-1661. | 30.7 | 599 |
| 20 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. <i>Nature Medicine</i> , 2015, 21, 81-85. | 30.7 | 594 |
| 21 | Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928. | 30.7 | 589 |
| 22 | Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472. | 28.4 | 576 |
| 23 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763. | 10.7 | 571 |
| 24 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639. | 1.2 | 549 |
| 25 | Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712. | 12.8 | 503 |
| 26 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137. | 1.6 | 446 |
| 27 | Skin-resident memory CD8 ⁺ T cells trigger a state of tissue-wide pathogen alert. <i>Science</i> , 2014, 346, 101-105. | 12.6 | 444 |
| 28 | Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. <i>Nature Medicine</i> , 2019, 25, 89-94. | 30.7 | 413 |
| 29 | Neoantigen landscape dynamics during human melanoma–T cell interactions. <i>Nature</i> , 2016, 536, 91-95. | 27.8 | 387 |
| 30 | Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. <i>Nature Medicine</i> , 2010, 16, 565-570. | 30.7 | 381 |
| 31 | Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. <i>Annals of Oncology</i> , 2019, 30, 998-1004. | 1.2 | 361 |
| 32 | Cancer immunotherapy “revisited”. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 591-600. | 46.4 | 346 |
| 33 | Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960. | 10.7 | 346 |
| 34 | Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. <i>JAMA Oncology</i> , 2019, 5, 164. | 7.1 | 329 |
| 35 | Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128. | 12.4 | 325 |
| 36 | Design and use of conditional MHC class I ligands. <i>Nature Medicine</i> , 2006, 12, 246-251. | 30.7 | 304 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw192. | 6.3 | 296 |
| 38 | Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. <i>Nature Methods</i> , 2009, 6, 520-526. | 19.0 | 286 |
| 39 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741. | 30.7 | 282 |
| 40 | In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. <i>Nature Medicine</i> , 2002, 8, 410-414. | 30.7 | 275 |
| 41 | Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 449-461. | 2.8 | 261 |
| 42 | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58. | 4.2 | 253 |
| 43 | Tissue-resident memory CD8 ⁺ T cells continuously patrol skin epithelia to quickly recognize local antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19739-19744. | 7.1 | 230 |
| 44 | Converting Cold into Hot Tumors by Combining Immunotherapies. <i>Cell</i> , 2017, 170, 1055-1056. | 28.9 | 212 |
| 45 | Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3. | 16.8 | 203 |
| 46 | Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018, 3, e000278. | 4.5 | 197 |
| 47 | Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263. | 30.7 | 190 |
| 48 | Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 4406-4412. | 1.6 | 177 |
| 49 | TIL therapy broadens the tumor-reactive CD8 ⁺ T cell compartment in melanoma patients. <i>Onc Immunology</i> , 2012, 1, 409-418. | 4.6 | 171 |
| 50 | Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161. | 1.2 | 170 |
| 51 | High-throughput identification of antigen-specific TCRs by TCR gene capture. <i>Nature Medicine</i> , 2013, 19, 1534-1541. | 30.7 | 166 |
| 52 | Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response. <i>Clinical Cancer Research</i> , 2008, 14, 2431-2436. | 7.0 | 163 |
| 53 | Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55. | 2.8 | 160 |
| 54 | An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. <i>Nature Medicine</i> , 2021, 27, 1250-1261. | 30.7 | 159 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Glutamyl cyclase is an enzymatic modifier of the CD47- SIRP α axis and a target for cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 612-619. | 30.7 | 156 |
| 56 | A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. <i>Nature Medicine</i> , 2005, 11, 899-904. | 30.7 | 153 |
| 57 | Acquired and intrinsic resistance in cancer immunotherapy. <i>Molecular Oncology</i> , 2014, 8, 1132-1139. | 4.6 | 153 |
| 58 | EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48. | 0.9 | 153 |
| 59 | Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66. | 0.1 | 151 |
| 60 | Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2657-2662. | 7.1 | 150 |
| 61 | Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 620-629. | 7.0 | 150 |
| 62 | Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>British Journal of Cancer</i> , 2010, 102, 803-809. | 6.4 | 146 |
| 63 | Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. , 2018, 6, 102. | | 141 |
| 64 | COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401. | 27.6 | 135 |
| 65 | ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448. | 1.2 | 132 |
| 66 | Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29. | 0.9 | 131 |
| 67 | Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. <i>EMBO Molecular Medicine</i> , 2015, 7, 1104-1118. | 6.9 | 129 |
| 68 | Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892. | 7.0 | 127 |
| 69 | Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 451-458. | 4.2 | 126 |
| 70 | Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188. | 30.7 | 121 |
| 71 | Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. <i>Journal of Clinical Oncology</i> , 2012, 30, e7-e10. | 1.6 | 119 |
| 72 | Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2019, 7, 6-11. | 3.4 | 118 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1681-1691. | 10.7 | 118 |
| 74 | Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2008, 99, 259-265. | 6.4 | 115 |
| 75 | Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542. | 7.0 | 114 |
| 76 | Fixed Dosing of Monoclonal Antibodies in Oncology. <i>Oncologist</i> , 2017, 22, 1212-1221. | 3.7 | 114 |
| 77 | Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 77-85. | 3.4 | 114 |
| 78 | Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolmmunology</i> , 2016, 5, e1238557. | 4.6 | 113 |
| 79 | Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1â€Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274. | 7.0 | 112 |
| 80 | Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants. <i>Journal of Experimental Medicine</i> , 1999, 190, 1319-1328. | 8.5 | 110 |
| 81 | The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2011, 60, 448-454. | 1.9 | 104 |
| 82 | Tumorâ€infiltrating lymphocytes for the treatment of metastatic cancer. <i>Molecular Oncology</i> , 2015, 9, 1918-1935. | 4.6 | 104 |
| 83 | CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9506-9506. | 1.6 | 101 |
| 84 | Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1241-1250. | 4.2 | 98 |
| 85 | Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604. | | 98 |
| 86 | Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2021, 12, 7348. | 12.8 | 96 |
| 87 | Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. <i>Blood</i> , 2007, 110, 3564-3572. | 1.4 | 95 |
| 88 | Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. <i>Molecular Therapy</i> , 2015, 23, 1541-1550. | 8.2 | 93 |
| 89 | Cryoablation and immunotherapy: an overview of evidence on its synergy. <i>Insights Into Imaging</i> , 2019, 10, 53. | 3.4 | 89 |
| 90 | Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF^{V600E}</i>-mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502. | 1.6 | 86 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2011, 22, 1041-1047. | 1.2 | 85 |
| 92 | NKG2A, a New Kid on the Immune Checkpoint Block. <i>Cell</i> , 2018, 175, 1720-1722. | 28.9 | 83 |
| 93 | Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136. | 1.1 | 82 |
| 94 | Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant. <i>Journal of Immunology</i> , 2006, 176, 5213-5222. | 0.8 | 81 |
| 95 | Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2014, 110, 2441-2449. | 6.4 | 81 |
| 96 | NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 32. | 4.4 | 81 |
| 97 | Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848. | | 79 |
| 98 | In situ detection of virus- and tumor-specific T-cell immunity. <i>Nature Medicine</i> , 2000, 6, 1056-1060. | 30.7 | 78 |
| 99 | Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317. | 6.7 | 78 |
| 100 | Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165. | 2.8 | 77 |
| 101 | Systemic T cell expansion during localized viral infection. <i>European Journal of Immunology</i> , 1999, 29, 1168-1174. | 2.9 | 76 |
| 102 | Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-101. | 1.6 | 75 |
| 103 | Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. <i>World Journal of Urology</i> , 2009, 27, 533-539. | 2.2 | 71 |
| 104 | Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 953-963. | 4.2 | 69 |
| 105 | Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. <i>Ophthalmology</i> , 2015, 122, 1907-1916. | 5.2 | 69 |
| 106 | ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461. | 1.2 | 69 |
| 107 | Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. <i>Annals of Oncology</i> , 2016, 27, 1138-1142. | 1.2 | 68 |
| 108 | Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. <i>Journal of Controlled Release</i> , 2010, 141, 234-240. | 9.9 | 67 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta Oncologica</i> , 2013, 52, 1786-1788. | 1.8 | 67 |
| 110 | Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization. <i>Journal of Immunology</i> , 2015, 195, 5285-5295. | 0.8 | 66 |
| 111 | Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184. | 2.8 | 65 |
| 112 | T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. <i>Journal of Immunotherapy</i> , 2008, 31, 1-6. | 2.4 | 63 |
| 113 | Regulation of Mycobacterial Heat-Shock Protein-Reactive T Cells by HLA Class II Molecules: Lessons from Leprosy. <i>Immunological Reviews</i> , 1991, 121, 171-191. | 6.0 | 61 |
| 114 | Targeting self-antigens through allogeneic TCR gene transfer. <i>Blood</i> , 2006, 108, 870-877. | 1.4 | 61 |
| 115 | BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 263-277. | 6.4 | 61 |
| 116 | Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178. | 2.8 | 61 |
| 117 | Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , 2017, 20, 205-215. | 7.2 | 59 |
| 118 | Tracing and characterization of the low-avidity self-specific T cell repertoire. <i>European Journal of Immunology</i> , 2000, 30, 1458-1468. | 2.9 | 58 |
| 119 | Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. <i>Angiogenesis</i> , 2009, 12, 69-79. | 7.2 | 58 |
| 120 | Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen. <i>Cancer Research</i> , 2008, 68, 8446-8455. | 0.9 | 57 |
| 121 | Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. <i>Seminars in Oncology</i> , 2015, 42, 423-428. | 2.2 | 55 |
| 122 | Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. <i>Human Gene Therapy</i> , 2009, 20, 181-189. | 2.7 | 54 |
| 123 | Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype. <i>Human Gene Therapy Methods</i> , 2014, 25, 277-287. | 2.1 | 54 |
| 124 | Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 97-105. | 2.2 | 53 |
| 125 | COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021, 27, 568-569. | 30.7 | 53 |
| 126 | Requirements for Effective Antitumor Responses of TCR Transduced T Cells. <i>Journal of Immunology</i> , 2008, 181, 5128-5136. | 0.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422. | 4.5 | 50 |
| 128 | Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9505-9505. | 1.6 | 50 |
| 129 | Preclinical development of T cell receptor gene therapy. <i>Current Opinion in Immunology</i> , 2009, 21, 209-214. | 5.5 | 48 |
| 130 | On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 4754-4760. | 7.0 | 47 |
| 131 | RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1173-1183. | 4.2 | 47 |
| 132 | The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021, 6, 100058. | 4.5 | 47 |
| 133 | The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. <i>Clinical Cancer Research</i> , 2020, 26, 4289-4301. | 7.0 | 46 |
| 134 | Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931. | | 46 |
| 135 | Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 641-648. | 3.9 | 46 |
| 136 | Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. <i>Laboratory Investigation</i> , 2007, 87, 161-172. | 3.7 | 45 |
| 137 | Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. <i>Vaccine</i> , 2008, 26, 3346-3351. | 3.8 | 45 |
| 138 | Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. <i>Acta Oncologica</i> , 2010, 49, 520-523. | 1.8 | 45 |
| 139 | A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019, 123, 58-71. | 2.8 | 45 |
| 140 | GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 70, 429-438. | 4.3 | 44 |
| 141 | Behavior and Function of Tissue-Resident Memory T cells. <i>Advances in Immunology</i> , 2012, 114, 203-216. | 2.2 | 44 |
| 142 | Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice. <i>Cancer Research</i> , 2004, 64, 2153-2161. | 0.9 | 42 |
| 143 | Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. <i>European Journal of Cancer</i> , 2005, 41, 386-392. | 2.8 | 42 |
| 144 | A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. <i>Annals of Oncology</i> , 2013, 24, 2098-2103. | 1.2 | 41 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Combination of targeted therapy and immunotherapy in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1359-1371. | 4.2 | 40 |
| 146 | Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab. <i>Clinical Nuclear Medicine</i> , 2013, 38, e182-e184. | 1.3 | 38 |
| 147 | Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells. <i>Cell Reports</i> , 2021, 37, 110013. | 6.4 | 38 |
| 148 | In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity. <i>Journal of Immunology</i> , 2007, 179, 2126-2133. | 0.8 | 37 |
| 149 | Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM). <i>Melanoma Research</i> , 2020, 30, 252-260. | 1.2 | 37 |
| 150 | Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology</i> , 2021, 22, e550-e561. | 10.7 | 37 |
| 151 | Optimizing the Efficacy of Epitope-Directed DNA Vaccination. <i>Journal of Immunology</i> , 2002, 168, 4998-5004. | 0.8 | 36 |
| 152 | A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). <i>Acta Oncologica</i> , 2011, 50, 121-126. | 1.8 | 36 |
| 153 | Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. <i>Oncotarget</i> , 2019, 8, e1648170. | 4.6 | 36 |
| 154 | A Redundant Role of the CD3 ζ -Immunoreceptor Tyrosine-Based Activation Motif in Mature T Cell Function. <i>Journal of Immunology</i> , 2001, 166, 2576-2588. | 0.8 | 35 |
| 155 | Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423. | 4.5 | 35 |
| 156 | Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. <i>Clinical Cancer Research</i> , 2006, 12, 2826-2833. | 7.0 | 34 |
| 157 | Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). <i>Cancer Research</i> , 2017, 77, CT075-CT075. | 0.9 | 34 |
| 158 | An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease. <i>Journal of Immunology</i> , 2008, 180, 6365-6373. | 0.8 | 33 |
| 159 | T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 5736-5747. | 7.0 | 33 |
| 160 | Vemurafenib As Neoadjuvant Treatment for Unresectable Regional Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e251-e253. | 1.6 | 33 |
| 161 | Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938. | 1.6 | 33 |
| 162 | Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses. <i>Human Gene Therapy</i> , 2012, 23, 1301-1312. | 2.7 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ. <i>Urology</i> , 2011, 78, 832-837. | 1.0 | 31 |
| 164 | Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. <i>International Journal of Cancer</i> , 2011, 129, 397-406. | 5.1 | 31 |
| 165 | Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. <i>European Journal of Immunology</i> , 2016, 46, 1351-1360. | 2.9 | 31 |
| 166 | Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. <i>Melanoma Research</i> , 2018, 28, 126-133. | 1.2 | 31 |
| 167 | Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. <i>European Journal of Immunology</i> , 2000, 30, 1297-1307. | 2.9 | 30 |
| 168 | Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology. <i>Otology and Neurotology</i> , 2019, 40, e674-e678. | 1.3 | 30 |
| 169 | Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 538-546. | 3.4 | 29 |
| 170 | Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). <i>European Urology</i> , 2019, 76, 437-440. | 1.9 | 29 |
| 171 | Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940. | 3.7 | 29 |
| 172 | Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry. <i>European Journal of Cancer</i> , 2021, 156, 24-34. | 2.8 | 29 |
| 173 | Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389. | 4.2 | 28 |
| 174 | Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA1-LBA1. | 1.6 | 28 |
| 175 | Targeted therapy for renal cell cancer: current perspectives. <i>Discovery Medicine</i> , 2010, 10, 394-405. | 0.5 | 28 |
| 176 | Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2013, 13, 561. | 2.6 | 27 |
| 177 | Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153. | 2.8 | 27 |
| 178 | Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470. | 5.1 | 27 |
| 179 | HLA Class-II-restricted Mycobacterium lepraereactive T-Cell Clones from Leprosy Patients Established with a Minimal Requirement for Autologous Mononuclear Cells. <i>Scandinavian Journal of Immunology</i> , 1986, 23, 101-108. | 2.7 | 26 |
| 180 | DNA Vaccines and Intradermal Vaccination by DNA Tattooing. <i>Current Topics in Microbiology and Immunology</i> , 2010, 351, 221-250. | 1.1 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Synthetic vehicles for DNA vaccination. <i>Journal of Drug Targeting</i> , 2010, 18, 1-14. | 4.4 | 26 |
| 182 | The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1307-1312. | 2.0 | 26 |
| 183 | Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472. | 4.5 | 26 |
| 184 | The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 503-515. | 4.2 | 26 |
| 185 | Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2011, 11, 505. | 2.6 | 25 |
| 186 | Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor- α -targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173. | 5.4 | 25 |
| 187 | Optimization of intradermal vaccination by DNA tattooing in human skin. <i>Human Gene Therapy</i> , 2008, 20, 081125111040089. | 2.7 | 24 |
| 188 | The impact of COVID-19 on oncology professionals' one year on: lessons learned from the ESMO Resilience Task Force survey series. <i>ESMO Open</i> , 2022, 7, 100374. | 4.5 | 24 |
| 189 | A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 713-719. | 4.2 | 23 |
| 190 | Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. <i>BMC Biotechnology</i> , 2007, 7, 2. | 3.3 | 23 |
| 191 | DNA tattoo vaccination: Effect on plasmid purity and transfection efficiency of different topoisomers. <i>Journal of Controlled Release</i> , 2009, 139, 153-159. | 9.9 | 23 |
| 192 | Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation. <i>AAPS PharmSciTech</i> , 2010, 11, 344-350. | 3.3 | 23 |
| 193 | Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. <i>Cancer Immunology Research</i> , 2017, 5, 170-179. | 3.4 | 23 |
| 194 | Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 501. | 7.1 | 23 |
| 195 | How I treat MSI cancers with advanced disease. <i>ESMO Open</i> , 2019, 4, e000511. | 4.5 | 23 |
| 196 | Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943. | | 23 |
| 197 | Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1227-1237. | 4.2 | 23 |
| 198 | Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9586-9586. | 1.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Long-Term Functionality of TCR-Transduced T Cells In Vivo. <i>Journal of Immunology</i> , 2008, 180, 6536-6543. | 0.8 | 22 |
| 200 | Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , 2019, 11, 1007. | 3.7 | 22 |
| 201 | Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323. | 2.6 | 22 |
| 202 | Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777. | 1.2 | 22 |
| 203 | Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients. <i>Journal of Immunotherapy</i> , 2007, 30, 234-239. | 2.4 | 21 |
| 204 | Validation of Serum Amyloid A as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. <i>European Urology</i> , 2012, 62, 685-695. | 1.9 | 21 |
| 205 | Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolimmunology</i> , 2016, 5, e1201625. | 4.6 | 21 |
| 206 | Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. <i>World Journal of Urology</i> , 2016, 34, 1067-1072. | 2.2 | 21 |
| 207 | Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 188-192. | 1.0 | 19 |
| 208 | A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX). <i>Future Oncology</i> , 2019, 15, 2203-2209. | 2.4 | 19 |
| 209 | Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1545-1552. | 5.0 | 19 |
| 210 | The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021, 6, 100199. | 4.5 | 19 |
| 211 | Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study. <i>European Journal of Cancer</i> , 2022, 167, 70-80. | 2.8 | 19 |
| 212 | The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , 2022, 150, 816-824. | 5.1 | 18 |
| 213 | Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835. | 10.7 | 18 |
| 214 | HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1163-1173. | 4.2 | 17 |
| 215 | Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). <i>Annals of Oncology</i> , 2017, 28, v622. | 1.2 | 17 |
| 216 | Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. <i>BMC Cancer</i> , 2018, 18, 895. | 2.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , 2020, 43, 256-264. | 2.4 | 17 |
| 218 | Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4574-4574. | 1.6 | 17 |
| 219 | Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524. | 1.6 | 17 |
| 220 | Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2575-2575. | 1.6 | 17 |
| 221 | Clonal dominance and selection for similar complementarity determining region 3 motifs among T lymphocytes responding to the HLA-DR3-associated <i>Mycobacterium leprae</i> heat shock protein 65-KD peptide 3â€“13. <i>Human Immunology</i> , 1995, 44, 220-227. | 2.4 | 16 |
| 222 | Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 926-931. | 4.2 | 16 |
| 223 | Do targeted agents offer clinical benefit as presurgical therapy?. <i>World Journal of Urology</i> , 2014, 32, 3-8. | 2.2 | 16 |
| 224 | A prospective observational registry evaluating clinical outcomes of Radiumâ€“223 treatment in a nonstudy population. <i>International Journal of Cancer</i> , 2020, 147, 1143-1151. | 5.1 | 16 |
| 225 | Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , 2020, 12, 2072. | 3.7 | 16 |
| 226 | First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , 2021, 124, 1222-1230. | 6.4 | 16 |
| 227 | Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. <i>European Journal of Cancer</i> , 2021, 144, 242-251. | 2.8 | 16 |
| 228 | Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003â€“2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119. | 2.8 | 16 |
| 229 | T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-Î³, TNF-Î± or IL-2 production. <i>Oncolmmunology</i> , 2021, 10, 1860482. | 4.6 | 16 |
| 230 | Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4611-4611. | 1.6 | 16 |
| 231 | Sunitinibâ€“induced changes in circulating endothelial cellâ€“related proteins in patients with metastatic renal cell cancer. <i>International Journal of Cancer</i> , 2012, 131, E484-93. | 5.1 | 15 |
| 232 | Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness. <i>BMC Cancer</i> , 2020, 20, 712. | 2.6 | 15 |
| 233 | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003. | 3.7 | 15 |
| 234 | Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4594-TPS4594. | 1.6 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 15 |
| 236 | Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment. European Urology Open Science, 2022, 35, 54-58. | 0.4 | 15 |
| 237 | Development and validation of an anion-exchange LC-LUV method for the quantification and purity determination of the DNA plasmid pDERMATT. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 282-288. | 2.8 | 14 |
| 238 | Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Therapy, 2012, 19, 303-311. | 4.6 | 14 |
| 239 | Clinical Pharmacokinetics of Vemurafenib in BRAF ^{v600E} Mutated Melanoma Patients. Journal of Clinical Pharmacology, 2017, 57, 125-128. | 2.0 | 14 |
| 240 | Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open, 2020, 5, e000945. | 4.5 | 14 |
| 241 | Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands â€” A nationwide population-based study. European Journal of Cancer, 2020, 137, 127-135. | 2.8 | 14 |
| 242 | Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519. | 4.2 | 14 |
| 243 | Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma? Cancer Treatment Reviews, 2013, 39, 305-312. | 7.7 | 13 |
| 244 | Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration ^{resistant} prostate cancer patients; a possible time relation. Prostate, 2016, 76, 32-40. | 2.3 | 13 |
| 245 | Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Annals of Oncology, 2017, 28, 862-867. | 1.2 | 13 |
| 246 | Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. OncoImmunology, 2020, 9, 1738814. | 4.6 | 13 |
| 247 | Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 544-544. | 1.6 | 13 |
| 248 | In situ visualization of antigen-specific T cells in cryopreserved human tissues. Journal of Immunological Methods, 2006, 310, 78-85. | 1.4 | 12 |
| 249 | Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65. | 4.4 | 12 |
| 250 | Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer, 2017, 17, 649. | 2.6 | 12 |
| 251 | Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. Journal of Biotechnology, 2019, 306, 100007. | 3.8 | 12 |
| 252 | LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. Annals of Oncology, 2020, 31, S1169. | 1.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 274.e1-274.e16. | 1.9 | 12 |
| 254 | Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245. | 2.8 | 12 |
| 255 | Discontinuation of anti-PD-1 monotherapy in advanced melanoma – Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326. | 5.1 | 12 |
| 256 | Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial. <i>BJU International</i> , 2022, 130, 68-75. | 2.5 | 12 |
| 257 | From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839. | 7.0 | 12 |
| 258 | Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7. <i>Vaccine</i> , 2012, 30, 4259-4266. | 3.8 | 11 |
| 259 | Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588. | 1.4 | 11 |
| 260 | Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578. | 1.4 | 11 |
| 261 | Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 319-329. | 4.2 | 11 |
| 262 | Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 498-506. | 3.3 | 11 |
| 263 | Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176. | 3.7 | 11 |
| 264 | Cellular Therapy and Cytokine Treatments for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 129-144. | 2.2 | 11 |
| 265 | Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2826. | 3.7 | 11 |
| 266 | Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835. | | 11 |
| 267 | HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547. | | 11 |
| 268 | Intradermal Vaccination by DNA Tattooing. <i>Methods in Molecular Biology</i> , 2014, 1143, 131-140. | 0.9 | 11 |
| 269 | Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 738-747. | 7.0 | 11 |
| 270 | [18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2010-2022. | 6.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 271 | Cytokine Therapy Response as a Selection Criterion for Cytoreductive Nephrectomy in Metastatic Renal Clear-Cell Carcinoma of Intermediate Prognosis. <i>Urologia Internationalis</i> , 2008, 80, 367-371. | 1.3 | 10 |
| 272 | Transposon leads to contamination of clinical pDNA vaccine. <i>Vaccine</i> , 2013, 31, 3274-3280. | 3.8 | 10 |
| 273 | Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016, 91, 267-273. | 1.9 | 10 |
| 274 | Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. <i>Journal of Immunotherapy</i> , 2018, 41, 413-425. | 2.4 | 10 |
| 275 | LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors. <i>Annals of Oncology</i> , 2021, 32, S1337. | 1.2 | 10 |
| 276 | Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. <i>ESMO Open</i> , 2021, 6, 100320. | 4.5 | 10 |
| 277 | Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?. <i>International Journal of Pharmaceutics</i> , 2010, 390, 32-36. | 5.2 | 9 |
| 278 | Tilting the AXIS towards therapeutic limits in renal cancer. <i>Lancet, The</i> , 2011, 378, 1898-1900. | 13.7 | 9 |
| 279 | Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis. <i>Journal of Thoracic Oncology</i> , 2020, 15, e15-e20. | 1.1 | 9 |
| 280 | Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 3083. | 3.7 | 9 |
| 281 | Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 248-255. | 3.9 | 9 |
| 282 | Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021, 13, 4639. | 3.7 | 9 |
| 283 | Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. <i>European Journal of Cancer</i> , 2021, 157, 225-237. | 2.8 | 9 |
| 284 | Immunotherapeutic strategies: the melanoma example. <i>Immunotherapy</i> , 2009, 1, 679-690. | 2.0 | 9 |
| 285 | MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. <i>Immuno-Oncology Technology</i> , 2022, 15, 100089. | 0.3 | 9 |
| 286 | Modest improvement in 20years of kidney cancer care in the Netherlands. <i>European Journal of Cancer</i> , 2012, 48, 1822-1830. | 2.8 | 8 |
| 287 | Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. <i>BMC Cancer</i> , 2016, 16, 364. | 2.6 | 8 |
| 288 | Observation After Cytoreductive Nephrectomy in Patients With Synchronous Not Completely Resected Metastases of Renal Cell Carcinoma. <i>Urology</i> , 2017, 109, 127-133. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332. | 1.2 | 8 |
| 290 | Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. <i>Cancer Research</i> , 2020, 80, 3412-3412. | 0.9 | 8 |
| 291 | The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-“foot syndrome. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2065-2072. | 1.9 | 7 |
| 292 | Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272. | 2.8 | 7 |
| 293 | BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. <i>Retinal Cases and Brief Reports</i> , 2022, 16, 430-434. | 0.6 | 7 |
| 294 | Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 189-203. | 3.8 | 7 |
| 295 | Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. <i>Melanoma Research</i> , 2022, 32, 460-468. | 1.2 | 7 |
| 296 | Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq0 0 0 rgBT /Overlock 10 T | 0.1 | 6 |
| 297 | Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 258.e7-258.e13. | 1.6 | 6 |
| 298 | Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135. | 4.2 | 6 |
| 299 | Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66. | 1.2 | 6 |
| 300 | Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer. <i>Cancer Research</i> , 2008, 68, 2455-2462. | 0.9 | 5 |
| 301 | Microbead-Assisted Retroviral Transduction for Clinical Application. <i>Human Gene Therapy</i> , 2010, 21, 1335-1342. | 2.7 | 5 |
| 302 | Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). <i>Annals of Oncology</i> , 2016, 27, vi386. | 1.2 | 5 |
| 303 | Transgenerational transfer of gene-modified T cells. , 2019, 7, 186. | | 5 |
| 304 | 1097P 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma: OpACIN trial. <i>Annals of Oncology</i> , 2020, 31, S742-S743. | 1.2 | 5 |
| 305 | IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel;) Tj ETQq1 1 0.784314 rgBT /Overlock 1 (Substudies 1 and 2).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11582-TPS11582. | 1.6 | 5 |
| 306 | A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4597-TPS4597. | 1.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 307 | Noadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection: REDUCTOR trial.. Journal of Clinical Oncology, 2019, 37, 9587-9587. | 1.6 | 5 |
| 308 | Vaccine leads to memory loss. Nature Medicine, 2007, 13, 248-250. | 30.7 | 4 |
| 309 | Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma. Annals of Oncology, 2019, 30, v481-v482. | 1.2 | 4 |
| 310 | Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. Journal of Clinical Oncology, 2021, 39, 4548-4548. | 1.6 | 4 |
| 311 | Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038. , 2017, , . | | 4 |
| 312 | Time to targeted therapy after cytoreductive nephrectomy (CN) and surveillance in patients with synchronous unresectable metastases of renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 604-604. | 1.6 | 4 |
| 313 | Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. Journal of Clinical Oncology, 2017, 35, 9539-9539. | 1.6 | 4 |
| 314 | 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients. Clinical Nuclear Medicine, 2022, 47, 583-589. | 1.3 | 4 |
| 315 | Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Clinica Chimica Acta, 2022, 533, 71-78. | 1.1 | 4 |
| 316 | DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives. Current Clinical Pharmacology, 2010, 5, 218-225. | 0.6 | 3 |
| 317 | Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma. Clinical and Experimental Immunology, 2010, 162, 447-459. | 2.6 | 3 |
| 318 | A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). Annals of Oncology, 2018, 29, viii465-viii466. | 1.2 | 3 |
| 319 | Cytoreductive nephrectomy in metastatic renal cancer â€” less is more. Nature Reviews Clinical Oncology, 2018, 15, 595-596. | 27.6 | 3 |
| 320 | Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4. Clinical Cancer Research, 2021, 27, 5389-5400. | 7.0 | 3 |
| 321 | The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, 3026-3026. | 1.6 | 3 |
| 322 | Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, TPS9592-TPS9592. | 1.6 | 3 |
| 323 | Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).. Journal of Clinical Oncology, 2018, 36, e18020-e18020. | 1.6 | 3 |
| 324 | Prognostic and predictive role of the tumor immune landscape. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 143-151. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. <i>British Journal of Cancer</i> , 2009, 101, 1224-1224. | 6.4 | 2 |
| 326 | Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 787-798. | 4.2 | 2 |
| 327 | Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs. <i>ESMO Open</i> , 2019, 4, e000557. | 4.5 | 2 |
| 328 | Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038. | 1.0 | 2 |
| 329 | Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 82-89. | 1.3 | 2 |
| 330 | A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4604-TPS4604. | 1.6 | 2 |
| 331 | Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9526-9526. | 1.6 | 2 |
| 332 | Immune checkpoint inhibition-related colitis: Correlation between ulcers and need for infliximab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21062-e21062. | 1.6 | 2 |
| 333 | A phase 2, single-arm trial of neoadjuvant axitinib plus avelumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4604-TPS4604. | 1.6 | 2 |
| 334 | Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021, 43, 539-541. | 0.6 | 2 |
| 335 | Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. <i>Clinical Cancer Research</i> , 2015, 21, 4251-4253. | 7.0 | 1 |
| 336 | Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. <i>Journal of Clinical Oncology</i> , 2017, 35, 3794-3795. | 1.6 | 1 |
| 337 | Questions asked in the everyday practice: immune checkpoint inhibitors. <i>ESMO Open</i> , 2018, 3, e000395. | 4.5 | 1 |
| 338 | Deep learning radiomics distinguishes intrapulmonary disease from metastases in immunotherapy-treated melanoma patients. <i>Annals of Oncology</i> , 2019, 30, v529. | 1.2 | 1 |
| 339 | Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4573-4573. | 1.6 | 1 |
| 340 | Dutch advanced melanoma care in times of COVID-19.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21502-e21502. | 1.6 | 1 |
| 341 | Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1 specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2) Tj ETQq1 106784314.rgBT /Oncol | | |
| 342 | Survival of stage IV melanoma in Belgium and the Netherlands. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, . | 2.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 4611-4611. | 1.6 | 1 |
| 344 | Cancer management in the era of immunotherapy: much more than meets the eye. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 141-142. | 0.7 | 1 |
| 345 | Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077. | 3.7 | 1 |
| 346 | A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial).. Journal of Clinical Oncology, 2016, 34, 4550-4550. | 1.6 | 1 |
| 347 | Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, TPS9602-TPS9602. | 1.6 | 1 |
| 348 | Abstract 4693: Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN). Cancer Research, 2018, 78, 4693-4693. | 0.9 | 1 |
| 349 | Abstract B022: Properties of T-cell-recognized neoantigens. , 2019, , . | | 1 |
| 350 | Re: Surgical Resection of Renal Cell Carcinoma After Targeted Therapy. Journal of Urology, 2010, 183, 1646-1647. | 0.4 | 0 |
| 351 | 1768 PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC). Journal of Urology, 2011, 185, . | 0.4 | 0 |
| 352 | Clinical Trial Design. , 2014, , 179-201. | | 0 |
| 353 | Single center experience on patients with advanced melanoma treated with short-term anti-CTLA4 directly followed by anti-PD-1. Annals of Oncology, 2016, 27, vi384. | 1.2 | 0 |
| 354 | Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial. Annals of Oncology, 2017, 28, v431. | 1.2 | 0 |
| 355 | EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy. Annals of Oncology, 2019, 30, v528. | 1.2 | 0 |
| 356 | Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma. Annals of Oncology, 2019, 30, v553. | 1.2 | 0 |
| 357 | A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. Oncolimmunology, 2019, 8, 1558664. | 4.6 | 0 |
| 358 | OP0165...EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , . | | 0 |
| 359 | Characterisation of rare haematological immune-related toxicities. Lancet Haematology,the, 2019, 6, e10-e11. | 4.6 | 0 |
| 360 | Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology, 2020, 11, 529-532. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 361 | An open-label phase II study comparing two doses of MK-6482 for the treatment of advanced renal cell carcinoma (RCC) following progression on prior systemic therapy.. Journal of Clinical Oncology, 2021, 39, TPS369-TPS369. | 1.6 | 0 |
| 362 | The power to â€œedi-sc-seq-tâ€™ Cancer Cell, 2021, 39, 299-301. | 16.8 | 0 |
| 363 | Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. Journal of Clinical Oncology, 2021, 39, e21523-e21523. | 1.6 | 0 |
| 364 | Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands.. Journal of Clinical Oncology, 2021, 39, e18641-e18641. | 1.6 | 0 |
| 365 | Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2021, 39, 4547-4547. | 1.6 | 0 |
| 366 | <i>BRAF</i> and <i>NRAS</i> mutation status and response to checkpoint inhibition in advanced melanoma.. Journal of Clinical Oncology, 2021, 39, 9558-9558. | 1.6 | 0 |
| 367 | Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.. Journal of Clinical Oncology, 2021, 39, 9544-9544. | 1.6 | 0 |
| 368 | Efficacy of checkpoint inhibition in advanced acral melanoma.. Journal of Clinical Oncology, 2021, 39, e21527-e21527. | 1.6 | 0 |
| 369 | Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers. , 2003, , 111-130. | | 0 |
| 370 | Volume of metastases and survival in patients with synchronous metastatic renal cell carcinoma (mRCC) of intermediate Memorial Sloan Kettering Cancer Center (MSKCC) prognosis.. Journal of Clinical Oncology, 2014, 32, e15605-e15605. | 1.6 | 0 |
| 371 | Abstract 4704: Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma. , 2015, , . | | 0 |
| 372 | Retrospective analysis of patients with advanced melanoma treated with short course of anti-CTLA4 directly followed by anti-PD-1.. Journal of Clinical Oncology, 2016, 34, e21011-e21011. | 1.6 | 0 |
| 373 | Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. Journal of Clinical Oncology, 2016, 34, e21058-e21058. | 1.6 | 0 |
| 374 | Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions. , 2016, , . | | 0 |
| 375 | Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. Journal of Clinical Oncology, 2017, 35, 514-514. | 1.6 | 0 |
| 376 | Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab.. Journal of Clinical Oncology, 2017, 35, 9572-9572. | 1.6 | 0 |
| 377 | Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.. Journal of Clinical Oncology, 2018, 36, 4572-4572. | 1.6 | 0 |
| 378 | Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.. Journal of Clinical Oncology, 2018, 36, 9585-9585. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Cytokines (IL-2, IFN GM-CSF etc) Melanoma. , 2019, , 1-31. | | 0 |
| 380 | Abstract B205: Adoptive transfer of autologous T-cells, modified with a MART-1 specific TCR and cultured in IL-7/IL-15, for the treatment of metastatic melanoma patients. , 2019, , . | | 0 |
| 381 | Abstract A185: Effective expansion of poly-functional tumor-reactive TILs from NSCLC correlates with an immune-engaged T-cell profile in tumor tissues. , 2019, , . | | 0 |
| 382 | Abstract B050: Identification of PD-1 TILs and CXCL13 as determinants for response to anti-PD-1 treatment using human tumor explants. , 2019, , . | | 0 |
| 383 | Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM). , 2019, , . | | 0 |
| 384 | Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma. , 2020, , 1109-1140. | | 0 |
| 385 | Immunotherapie van kanker. , 2020, , 191-201. | | 0 |
| 386 | Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME.. Journal of Clinical Oncology, 2020, 38, 703-703. | 1.6 | 0 |
| 387 | New milestones for IOTTECH in 2022. Immuno-Oncology Technology, 2021, 12, 100060. | 0.3 | 0 |
| 388 | TIL classified to memory state are correlated with response to immune checkpoint blockade. Cell Reports Medicine, 2022, 3, 100669. | 6.5 | 0 |
| 389 | Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVVEC trial.. Journal of Clinical Oncology, 2022, 40, TPS9607-TPS9607. | 1.6 | 0 |